New blood marker could speed up diagnosis of deadly gut condition
NCT ID NCT03671928
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether a substance called glicentin in the blood can help diagnose intestinal ischemia, a condition where blood flow to the gut is blocked. Researchers measured glicentin levels in 54 people with suspected ischemia and compared them to a control group. The goal is to find a better, faster way to diagnose this serious condition, which currently has poor diagnostic tools.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a new blood test to diagnose intestinal ischemia faster and more accurately, potentially saving lives.
- What could go wrong
- This is a small, early-stage study with only 54 participants. The results may not be strong enough to create a reliable test, and the findings need confirmation in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
54 people
The number who actually took part.
- Started
-
Feb 2020
- Finished
-
Mar 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * For patients with intestinal ischemia * The combination of abdominal pain, altered general condition with abdominal defence and venous or arterial hyperlactatemia will be signs suggestive of a diagnosis of digestive ischemia. * Patients suspected of digestive ischemia with the following comorbidities may be included as clinical suspicion and excluded post-operatively: emboligenic heart disease, arteriopathy, aortic and/or digestive atheromatosis. * Patients with suspected digestive ischemia and functional scanning ileus. * Patients with intestinal ischemia proven by CT scan with contrast injection: arterial abnormality such as dissection of an artery for digestive use, thrombosis or embolism of an artery for digestive use; intestinal or colonic thickening suggestive of reversible ischemic suffering of the digestive tract; parietal pneumatosis; gastrointestinal parietal enhancement abnormality (hypo-density ranges or total absence of enhancement). The following pathologies will be taken into account: mesenteric ischemia by embolism or thrombosis. * Age over 18 years old * Able to understand the study * Affiliation to a social security system * Signing of an informed consent * Accept participation in the study (collection of a Non-Opposition) For the control group * Age over 18 years old * Able to understand the study * Affiliation to a social security system * Signing of an informed consent * No personal history of colorectal cancer and obesity * Admission to the Emergency Department of the University Hospital of Nice for abdominal pain with EVA \> 3/10 of non-intestinal origin: nephritic colic, hepatobiliary pathology, gynaecological disease, etc. * Abdominal CT excluding digestive tract pathology * Accept participation in the study Exclusion Criteria: * History of bariatric or digestive surgery (stomach, small intestine, colon or rectum) * History of chronic inflammatory bowel disease * Obese patients (BMI\> 30kg/m2) * History of type 1 diabetes or insulin treatment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ischemia bowel are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Nice Hospital
Nice, 06000, France